A combination of resveratrol and melatonin exerts chemopreventive effects in N-methyl-N-nitrosourea-induced rat mammary carcinogenesis

European Journal of Cancer Prevention

Volumn 21, Issue 2, 2012, Pages 163-170

  Kisková, Terézia ^a   Ekmekcioglu, Cem ^b,e   Garajová, Miroslava ^a   Orendáš, Peter ^a   Bojková, Bianka ^a   Bobrov, Nikita ^a   Jäger, Walter ^d   Kassayová, Monika ^a   Thalhammer, Theresia ^c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Breast cancer; Melatonin; N methyl N nitrosourea; Resveratrol

Indexed keywords

CARCINOGEN; CYCLINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MELATONIN; MELATONIN 1 RECEPTOR; METHYLNITROSOUREA; RESVERATROL; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; CANCER INCIDENCE; CARCINOMA IN SITU; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOOD INTAKE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT DURATION; TUMOR VOLUME;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOGENS; CARCINOMA; CHEMOPREVENTION; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR ALPHA; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; METHYLNITROSOUREA; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858275962     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32834c9c0f     Document Type: Article

References (43)

1. Ali S, Coombes RC (2000). Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 5:271-281. (Pubitemid 32156528)
2. Banerjee S, Bueso-Ramos C, Aggarwal BB (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62:4945-4954. (Pubitemid 34984418)
3. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM (2001). Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61:7456-7463. (Pubitemid 32995034)
4. Bojkova B, Kubatka P, Mocikova K, Mnichova M, Ahlersova E, Ahlers I (2000). Effects of retinyl acetate and melatonin on N-methyl-N-nitrosourea- induced mammary carcinogenesis in rats: a preliminary report. Folia Biol (Praha) 46:73-76. (Pubitemid 30235018)
5. Bojkova B, Garajova M, Kajo K, Pec M, Kubatka P, Kassayova M, et al. (2010). Pioglitazone in chemically induced mammary carcinogenesis in rats. Eur J Cancer Prev 19:379-384.
6. Bove K, Lincoln DW, Tsan MF (2002). Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 291:1001-1005. (Pubitemid 34694375)
7. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM (2000). Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141:3657-3667.
8. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argiles JM, et al. (2007). Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144-148. (Pubitemid 44959346)
9. Clemens JW, Jarzynka MJ, Witt-Enderby PA (2001). Down-regulation of mt1 melatonin receptors in rat ovary following estrogen exposure. Life Sci 69:27-35. (Pubitemid 32523931)
10. Del Rio B, Garcia Pedrero JM, Martinez-Campa C, Zuazua P, Lazo PS, Ramos S (2004). Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin. J Biol Chem 279:38294-38302. (Pubitemid 39295977)
11. Ekmekcioglu C (2006). Melatonin receptors in humans: biological role and clinical relevance. Biomed Pharmacother 60:97-108.
12. Fukui M, Yamabe N, Kang KS, Zhu BT (2010). Growth-stimulatory effect of resveratrol in human cancer cells. Mol Carcinog 49:750-759.
13. Garvin S, Ollinger K, Dabrosin C (2006). Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231:113-122. (Pubitemid 41779459)
14. Goldberg DM, Yan J, Soleas GJ (2003). Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36:79-87. (Pubitemid 36126394)
15. Goswami SK, Das DK (2009). Resveratrol and chemoprevention. Cancer Lett 284:1-6.
16. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L (2009). Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 8:337-346.
17. Hoang BX, Shaw DG, Pham PT, Levine SA (2007). Neurobiological effects of melatonin as related to cancer. Eur J Cancer Prev 16:511-516. (Pubitemid 350307500)
18. Hsieh TC (2009). Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormonenon-responsive CWR22Rv1 cells. Anticancer Res 29:3011-3017.
19. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, et al. (2000). Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 74:279-285. (Pubitemid 32126240)
20. Kwon KJ, Kim JN, Kim MK, Lee J, Ignarro LJ, Kim HJ, et al. (2011). Melatonin synergistically increases resveratrol-induced heme oxygenase-1 expression through the inhibition of ubiquitin-dependent proteasome pathway: a possible role in neuroprotection. J Pineal Res 50:110-123.
21. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F (2001). ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130. (Pubitemid 32802685)
22. Lenoir V, de Jonage-Canonico MB, Perrin MH, Martin A, Scholler R, Kerdelhue B (2005). Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 7:R470-R476.
23. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward JE III, et al. (2003). Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha. Int J Cancer 104:587-596. (Pubitemid 36337258)
24. Lopez-Burillo S, Tan DX, Mayo JC, Sainz RM, Manchester LC, RJ Reiter (2003). Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alpha-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res 34:269-277. (Pubitemid 36469773)
25. Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG (2008). Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10 F cells. Cancer Prev Res (Phila) 1:135-145.
26. Mocikova-Kalicka K, Bojkova B, Adamekova E, Mnichova-Chamilova M, Kubatka P, Ahlersova E, et al. (2001). Preventive effect of indomethacin and melatonin on 7, 12-dimethybenz/a/anthracene-induced mammary carcinogenesis in female Sprague-Dawley rats: a preliminary report. Folia Biologica 47:75-79. (Pubitemid 32266555)
27. Mills E, Wu P, Seely D, Guyatt G (2005). Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res 39:360-366.
28. Niu XF, Liu BQ, Du ZX, Gao YY, Li C, Li N, et al. (2011). Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1. BMC cancer 11:99.
29. Orendas P, Kassayova M, Kajo K, Ahlers I, Kubatka P, Bojkova B, et al. (2009). Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. Neoplasma 56:252-258.
30. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004). Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428. (Pubitemid 38114127)
31. Pozo-Guisado E, Lorenzo-Benayas MJ, Fernandez-Salguero PM (2004). Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 109:167-173. (Pubitemid 38240916)
32. Reiter RJ, Paredes SD, Manchester LC, Tan DX (2009). Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Cr Rev Biochem Mol Biol 44:175-200.
33. Remmele W, Stegner HE (1987). [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 8:138-140.
34. Rice S, Whitehead SA (2006). Phytoestrogens and breast cancer: promoters or protectors? Endocr Relat Cancer 13:995-1015. (Pubitemid 46217691)
35. Rogelsperger O, Ekmekcioglu C, Jager W, Klimpfinger M, Konigsberg R Krenbek D, et al. (2009). Coexpression of the melatonin receptor 1 and nestin in human breast cancer specimens. J Pineal Res 46:422-432.
36. Saez MC, Barriga C, Garcia JJ, Rodriguez AB, Masot J, Duran E, et al. (2005). Melatonin increases the survival time of animals with untreated mammary tumours: neuroendocrine stabilization. Mol Cell Biochem 278:15-20. (Pubitemid 41418915)
37. Sanchez-Barcelo EJ, Cos S, Fernandez R, Mediavilla MD (2003). Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10:153-159. (Pubitemid 36758644)
38. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C (2005). Melatonin-estrogen interactions in breast cancer. J Pineal Res 38:217-222. (Pubitemid 41475432)
39. Shankar S, Singh G, Srivastava RK (2007). Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12:4839-4854.
40. Trapp V, Parmakhtiar B, Papazian V, Willmott L, Fruehauf JP (2010). Antiangiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 13:305-315.
41. Treeck O, Haldar C, Ortmann O (2006). Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15:231-235.
42. Whitsett T, Carpenter M, Lamartiniere CA (2006). Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5:15.
43. Williams GP (2010). The role of oestrogen in the pathogenesis of obesity, type 2 diabetes, breast cancer and prostate disease. Eur J Cancer Prev 19:256-271.